The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Drug Repurposing (DR): An Emerging Approach in Drug Discovery
Open accessAbstract
Drug repurposing (DR) (also known as drug repositioning) is a process of identifying new therapeutic use(s) for old/existing/available drugs. It is an effective strategy in discovering or developing drug molecules with new pharmacological/therapeutic indications. In recent years, many pharmaceutical companies are developing new drugs with the discovery of novel biological targets by applying the drug repositioning strategy in drug discovery and development program. This strategy is highly efficient, time saving, low-cost and minimum risk of failure. It maximizes the therapeutic value of a drug and consequently increases the success rate. Thus, drug repositioning is an effective alternative approach to traditional drug discovery process. Finding new molecular entities (NME) by traditional or de novo approach of drug discovery is a lengthy, time consuming and expensive venture. Drug repositioning utilizes the combined efforts of activity-based or experimental and in silico-based or computational approaches to develop/identify the new uses of drug molecules on a rational basis. It is, therefore, believed to be an emerging strategy where existing medicines, having already been tested safe in humans, are redirected based on a valid target molecule to combat particularly, rare, difficult-to-treat diseases and neglected diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Drug repositioning: a brief overview
Jourdan, J.-P., Bureau, R., Rochais, C., & Dallemagne, P. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13273 · Cited by 470 · cited 1×
“Some regulatory issues that are commonly encountered in drug repositioning are described as follows [37, 38].”
BackgroundDrug repositioning: a machine-learning approach through data integration
Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, R., Kere, J., D’Amato, M., & Greco, D. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-30 · Cited by 349
Cited by
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Drug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 257
Kaushal, J., Bhatia, R., Kanchan, R., Raut, P., Mallapragada, S., Ly, Q., Batra, S., & Rachagani, S. (2021) · Cancers · doi:10.3390/cancers13133105 · Cited by 35
DiffDec: Structure-Aware Scaffold Decoration with an End-to-End Diffusion Model
Xie, J., Chen, S., Lei, J., & Yang, Y. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01466 · Cited by 31
Metadata
- Authors
- Rudrapal, M., J. Khairnar, S., & G. Jadhav, A.
- Venue
- Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
- Publisher
- IntechOpen
- Published
- 2020-12-02
- OpenAlex
- W3044296243
- Cited by
- 207
- References
- 5
- FWCI
- 86.41
- Type
- book chapter
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.